enGene Therapeutics (ENGN) Change in Accured Expenses (2023 - 2026)

enGene Therapeutics (ENGN) has reported Change in Accured Expenses for 4 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses fell 163.44% year-over-year to -$2.5 million; the TTM figure through Apr 2026 stood at $5.0 million (up 85.17% YoY), while the FY2025 annual figure was $3.1 million, down 40.1% from the prior year.
• Change in Accured Expenses retreated to -$2.5 million in Q2 2026 per ENGN's latest filing, from $4.4 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.4 million in Q1 2026 and bottomed at -$3.9 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $794571.4 across 4 years, with a median of $293000.0 in 2023.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 1760.47% — and 2025, when it sank 280.38%.
• enGene Therapeutics' Change in Accured Expenses stood at $3.0 million in 2023, then plunged by 118.2% to -$540000.0 in 2024, then soared by 869.26% to $4.2 million in 2025, then plunged by 159.82% to -$2.5 million in 2026.
• Business Quant data shows ENGN's Change in Accured Expenses at -$2.5 million in Q2 2026, $4.4 million in Q1 2026, and $4.2 million in Q4 2025.